Qiagen (QGEN) EBITDA Margin (2009 - 2025)

Qiagen (QGEN) posted EBITDA Margin of 113.99% for Q4 2025, up 370.0% sequentially from 24.25% in Q3 2025, and up 5461.0% YoY from 2.05% in Q4 2024.

Qiagen (QGEN) EBITDA Margin (2009 - 2025) Analysis & Trends

Qiagen has reported EBITDA Margin for 17 years, with the latest figure at 113.99% in Q4 2025.

Quarterly EBITDA Margin rose 5461.0% year-over-year to 113.99% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 50.2% (up 1131.0% YoY) and the FY2025 annual result came in at 29.47%, up 81.0% from the prior year.
EBITDA Margin improved to 113.99% in Q4 2025 per QGEN's latest filing, from 24.25% in the prior quarter.
Over five years, EBITDA Margin peaked at 113.99% in Q4 2025 and troughed at 19.55% in Q3 2022.
A 5-year average of 39.3% and a median of 28.41% in 2024 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2023 and 2024: EBITDA Margin jumped 7679 bps in 2023, then slumped 4452 bps in 2024.
Over 5 years, EBITDA Margin stood at 66.52% in 2021, then sank by 59 bps to 27.11% in 2022, then soared by 283 bps to 103.9% in 2023, then plunged by 43 bps to 59.37% in 2024, then surged by 92 bps to 113.99% in 2025.
According to Business Quant data, EBITDA Margin over the past three periods registered 113.99%, 24.25%, and 29.99% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Thermo Fisher Scientific	213.88 Bn	209.81 Bn	8.34 Bn	17.40%
2	Danaher	140.65 Bn	136.30 Bn	3.61 Bn	17.99%
3	Idexx Laboratories	46.02 Bn	45.83 Bn	779.09 Mn	34.98%
4	Agilent Technologies	39.85 Bn	38.05 Bn	990.00 Mn	21.74%
5	Iqvia Holdings	39.20 Bn	37.12 Bn	1.44 Bn	11.58%
6	Natera	38.80 Bn	37.70 Bn	696.04 Mn	-13.42%
7	Illumina	30.11 Bn	28.94 Bn	770.00 Mn	21.14%
8	Mettler Toledo International	28.66 Bn	28.61 Bn	650.22 Mn	31.97%
9	Quest Diagnostics	26.24 Bn	25.61 Bn	1.03 Bn	15.08%
10	Qiagen	8.65 Bn	8.65 Bn	-	-

Download Data